Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Syndax Pharmaceuticals Inc (1T3)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
19.0000 -0.6000    -3.06%
02:01:59 - Delayed Data. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  US87164F1057 
S/N:  A2AFL6
  • Volume: 0
  • Bid/Ask: 19.0000 / 19.9000
  • Day's Range: 19.0000 - 19.0000
Syndax Pharmaceuticals 19.0000 -0.6000 -3.06%

Syndax Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Syndax Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

107

Equity Type

ORD

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Contact Information

Address 35 Gatehouse Drive Building D
Floor 3 Waltham, 02451
United States
Phone 781 419 1400
Fax -

Top Executives

Name Age Since Title
Dennis G. Podlesak 63 2008 Independent Chairman
Michael A. Metzger 51 2015 CEO & Director
Jedd D. Wolchok - 2016 Member of Scientific Advisory Board
Hope S. Rugo - 2016 Member of Scientific Advisory Board
Lisa M. Coussens - 2017 Member of Scientific Advisory Board
Samir N. Khleif 58 2016 Member of Scientific Advisory Board
Jennifer Jarrett 51 2018 Independent Director
William Meury 54 2018 Independent Director
Martin H. Huber 61 2021 Independent Director
Julie R. Brahmer - 2015 Member of Scientific Advisory Board
George W. Sledge 71 2014 Member of Scientific Advisory Board
Keith A. Katkin 52 2017 Independent Director
Pierre Legault 62 2017 Independent Director
Briggs W. Morrison 63 2015 Director
Joseph Paul Eder - 2016 Member of Scientific Advisory Board & Chief Medical Officer
Ronald M. Evans 75 2016 Co-Founder, Advisor and Chair of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SNDX Comments

Write your thoughts about Syndax Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Lim Xy
Lim Xy Jul 01, 2021 8:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy now👍
Anand Guru
Anand Guru Apr 29, 2021 2:37PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Quick Buy call on ADVM. CMP 4.0 fell 60% today.. going to recover 40% in one hour. Hurry make your profit 40% today..
Anand Guru
Anand Guru Apr 26, 2021 12:11PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Strong buy call with 30% upside today. Buy SNDX pharma CMP: 15.95 today target 21$
Anand Guru
Anand Guru Apr 26, 2021 12:14AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Company chairman bought $197k worth shares very recently at 14.10..tjose who have webul account please check News info of this share... Very good positivr sign for share price to climb up drastically. Short term target before May expiry 42$ per share. Share may rise sharply tomorro..
Anand Guru
Anand Guru Apr 23, 2021 2:54PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Mark my words the graph is very strong and any time may shootup strongly
Anand Guru
Anand Guru Apr 23, 2021 1:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Strong upside seen in intraday chart.. any time will break today high..
Anand Guru
Anand Guru Apr 23, 2021 1:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
String upside seen in intraday chart.. any time will break today high
Anand Guru
Anand Guru Apr 23, 2021 12:29PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Morning All, One more Quick Buy call on SNDX pharma. CMP 14.98 intraday target 17.40$.. hurry quick buy before surges.. next week 25$ target.. bet in options and make huge returns
Testo Sterone
Testo Sterone Apr 22, 2021 5:14PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Form 4 for director buying over 13000 shares at $14.11 average
Richard Daroi
Richard Daroi Apr 22, 2021 5:14PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
sources?
Anand Guru
Anand Guru Apr 22, 2021 2:06PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy now at 14.01..
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email